Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

被引：8

作者：

Laza-Briviesca, R. ^{[1
]}

Cruz-Bermudez, A. ^{[1
]}

Casarrubios, M. ^{[1
]}

Nadal, E. ^{[2
]}

Insa, A. ^{[3
]}

Garcia Campelo, R. ^{[4
]}

De Dios Alvarez, N. ^{[5
]}

Domine, M. ^{[6
]}

Majem, M. ^{[7
]}

Rodriguez-Abreu, D. ^{[8
]}

Calvo De Juan, V. ^{[1
]}

Martinez-Marti, A. ^{[9
,10
]}

De Castro Carpeno, J. ^{[11
]}

Cobo, M. ^{[12
]}

Lopez-Vivanco, G. ^{[13
]}

Del Barco, E. ^{[14
]}

Bernabe, R. ^{[15
]}

Vinolas, N. ^{[16
]}

Barneto, I. ^{[17
]}

Viteri, S. ^{[18
]}

Massuti, B. ^{[19
]}

Provencio, M. ^{[1
]}

机构：

[1] Hosp Univ Puerta de Hierro Majadahonda, Inst Invest Sanitaria Puerta de Hierro Majadahond, Serv Oncol Med, Madrid, Spain

[2] Inst Catala Oncol, Med Oncol, Barcelona, Spain

[3] Hosp Clin Univ, Clin Fdn Incliva, Valencia, Spain

[4] Hosp Univ A Coruna, La Coruna, Spain

[5] Hosp Univ Vigo, Pontevedra, Spain

[6] Hosp Fdn Jimenez Iis Fjd, Madrid, Spain

[7] Hosp La Santa Creu & St Pau, Barcelona, Spain

[8] Hosp Insular Gran Canaria, Las Palmas Gran Canaria, Spain

[9] Vall Dhebron Univ Hosp, Barcelona, Spain

[10] Inst Oncol Vhio, Barcelona, Spain

[11] Hosp Univ La Paz, Madrid, Spain

[12] Univ Hosp Reg Malaga, Malaga, Spain

[13] Hosp Univ Cruces, Baracaldo, Spain

[14] Hosp Univ Salamanca, Salamanca, Spain

[15] Hosp Univ Virgen Del Rocio, Seville, Spain

[16] Clin Hosp, Oncol, Barcelona, Spain

[17] Hosp Univ Reina Sofia, Cordoba, Spain

[18] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell, Grp Quironsalud, Barcelona, Spain

[19] Hosp Gen Alicante, Alicante, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

stage IIIA NSCLC; biomarkers; neo-adjuvant chemo-immunotherapy;

D O I：

10.1016/j.jtho.2019.08.1515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.04-10

引用

页码：S711 / S711

页数：1

共 50 条

[41] SALVAGE THERAPY FOR STAGE-II OR STAGE-III BREAST-CARCINOMA PATIENTS (PTS) FAILING ADJUVANT CHEMO-IMMUNOTHERAPY
RABADI, S
HAID, M
KHANDEKAR, J
OVIEDO, M
CUNNINGHAM, M
CAPRINI, J
SCANLON, E
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 434 - 434
[42] Concordance Between Clinical and Pathological Response Assessment After Neo-Adjuvant Chemotherapy in Patients With Invasive Lobular Carcinoma
Shaikh, Aisha
Tariq, Muhammad Usman
Khan, Shaista Masood
Idress, Romana
Vohra, Lubna M.
Shaikh, Saira Fatima
Waheed, Hira
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
[43] Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy
Cecchin, E.
Agostini, M.
Pucciarelli, S.
De Paoli, A.
Canzonieri, V.
Sigon, R.
De Mattia, E.
Friso, M. L.
Biason, P.
Visentin, M.
Nitti, D.
Toffoli, G.
PHARMACOGENOMICS JOURNAL, 2011, 11 (03): : 214 - 226
[44] NEO-ADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN PATIENTS WITH STAGE IIIA (N2) NON-SMALL CELL LUNG CANCER (NSCLC). A RETROSPECTIVE ANALYSIS WITH LESSONS LEARNED
Friedman, Eliot
Szwerc, Michael
Andrews, Charles
Kruklitis, Robert
Santiago, Ferdy
Leies, Kathleen
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1575 - S1575
[45] Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapy
Yu, Chih-Chin
Chang, Chao-Hsiang
Fang, Jen-Kai
Huang, Steven K.
Tseng, Wen-Hsin
Lee, Hsiang-Ying
Yeh, Hsin-Chih
Chen, I-Hsuan Alan
Lin, Jen-Tai
Chen, Pi-Che
Cheong, Ian-Seng
Hsueh, Thomas Y.
Jiang, Yuan -Hong
Lee, Yu-Khun
Chen, Wei-Chieh
Lo, Shih-Hsiu
Lin, Po -Hung
Wang, Shian-Shiang
Huang, Chao -Yuan
Wu, Chia -Chang
Tseng, Jen-Shu
Wu, Shu-Yu
Tsai, Yao-Chou
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (12) : 1274 - 1281
[46] Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy
E Cecchin
M Agostini
S Pucciarelli
A De Paoli
V Canzonieri
R Sigon
E De Mattia
M L Friso
P Biason
M Visentin
D Nitti
G Toffoli
The Pharmacogenomics Journal, 2011, 11 : 214 - 226
[47] High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial.
Provencio, Mariano
Serna-Blasco, Roberto
Nadal, Ernest
Insa, Amelia
Rosario Garcia-Campelo, M.
Pereiro Corbacho, Diego
Domine, Manuel
Majem, Margarita
Rodriguez-Abreu, Delvys
Martinez-Marti, Alex
de Castro, Javier
Cobo, Manuel
Lopez-Vivanco, Guillermo
del Barco, Edel
Bernabe, Reyes
Vinolas, Nuria
Barneto, Isidoro
Viteri, Santiago
Pereira, Eva
Royuela, Ana
Casarrubios, Marta
Salas, Clara
Parra, Edwin R.
Wistuba, Ignacio
Calvo, Virginia
Laza-Briviesca, Raquel
Massuti, Bartomeu
Cruz-Vermudez, Alberto
Romero, Atocha
CANCER RESEARCH, 2021, 81 (13)
[48] ERCC1-GENE EXPRESSION AS A RESPONSE PREDICTIVE MARKER TO NEO-ADJUVANT THERAPY WITH CISPLATIN AND DOCETAXEL IN STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER (NSCLC)
Buffoni, Lucio
Ruffini, Enrico
Filippi, Andrea Riccardo
Consito, Lorena T.
Mantovani, Cristina
Bironzo, Paolo
Paze, Enrica
Birocco, Nadia
Milanesi, Enrica
Oliaro, Alberto
Ricardi, Umberto
Schena, Marina
Ciuffreda, L.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1073 - S1074
[49] Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates
Couvreur, Karen
Naert, Eline
De Jaeghere, Emiel
Tummers, Philippe
Makar, Amin
De Visschere, Pieter
Van Bockstal, Mieke
Van Dorpe, Jo
De Neve, Wilfried
Denys, Hannelore
Vandecasteele, Katrien
BMC CANCER, 2018, 18
[50] Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates
Karen Couvreur
Eline Naert
Emiel De Jaeghere
Philippe Tummers
Amin Makar
Pieter De Visschere
Mieke Van Bockstal
Jo Van Dorpe
Wilfried De Neve
Hannelore Denys
Katrien Vandecasteele
BMC Cancer, 18

← 1 2 3 4 5 →